As part of Sangamo Therapeutics' Chapter 11 filing, Astellas Pharma agreed to acquire Sangamo's Fabry disease gene therapy program isaralgagene civaparvovec (ST-920) for $25 million at closing plus up to $25 million in milestone payments. Astellas serves as the stalking-horse bidder under a Section 363 sale process subject to a court-supervised auction.